logo
logo

RenBio Announces New Awards for DNA-Based MYO Technology™ Platform for Antiviral Applications

RenBio Announces New Awards for DNA-Based MYO Technology™ Platform for Antiviral Applications

07/25/24, 11:45 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgnew york
Money
$3.64 million
Industry
therapeutics
biotechnology
health care
Type
partnership
RenBio announced that it has received funding to evaluate DNA-based delivery of antiviral antibodies for Zika and influenza prevention, including a $2.9 million award from Wellcome and a $749,000 contract award supported by federal funds from the Biomedical Advanced Research and Development Authority (BARDA), as part of the Flexible and Strategic Therapeutics (FASTx) Program. The awards will boost the potential of RenBio's proprietary MYO Technology platform to deliver next-generation DNA medicines for infectious disease prevention.

Company Info

Company
RenBio
Location
new york, new york, united states
Additional Info
RenBio is a privately held, preclinical biotechnology company leveraging its novel, proprietary MYO (Make Your Own) Technology™ platform to deliver next-generation antibody and protein medicines in the form of DNA therapeutics.